Identification of RE1-Silencing Transcription Factor as a Promoter of Metastasis in Pancreatic Cancer

In conclusion, our results of bioinformatic analysis, in vitro and in vivo functional analysis suggested that REST may serve as a promoter of metastasis in pancreatic cancer. Introduction Pancreatic cancer, ranked fourth in cancer-related mortality, is characterized by its rapid progression and early metastasis (1). Patients are hardly cured by surgical resection due to the existing local invasion and distant metastasis (2). Elevating the overall survival rate for pancreatic cancer requires further elucidation of the underlying molecular mechanism of its metastasis. Epithelial-mesenchymal transition (EMT), especially type III EMT, is reported to be one of the primal steps for cancer cells' local invasion and distant metastasis (3, 4). It is a complicated process in which cancer cells transit from a rather dominant epithelial phenotype to a more invasive and metastatic mesenchymal phenotype (5). This process is characterized by alterations in the expression level of multiple proteins leading to the loss of cell junctions and apical-basal polarity in cancer cells. Therefore, identification of key genes regulating EMT and cancer metastasis possesses great clinical significance (6). These genes could be predictive biomarkers for cancer metastasis and novel therapy targets for anti-cancer drugs. The Cancer Genome Atlas (TCGA) is a comprehensive cancer genomic database (7). All of its cancer tissue and matched normal tissue samples were collected and further analyzed...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Source: Biological Rhythm Research - Category: Research Authors: Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Hyun Ji Son, Ha Yoon Mo, Nam Jin Yoo, Sug Hyung Lee
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Jamal Halajzadeh, Parisa Maleki Dana, Zatollah Asemi, Mohammad Ali Mansournia, Bahman Yousefi
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 12 July 2020Source: Pathology - Research and PracticeAuthor(s): Milena Vuletic, Snezana Jancic, Sanja Milenkovic, Marinko Paunovic, Biljana Milicic, Nina Jancic, Biljana Perunicic, Zivana Slovic
Source: Pathology Research and Practice - Category: Pathology Source Type: research
BOWEL cancer affects a person's digestive system in a number of ways. Tenesmus is one of the warning symptoms relating to digestion. The condition could signal early bowel cancer. What is tenesmus?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Could this technique help promote wound healing among oncology patients with complex wounds?Wounds
Source: Medscape Today Headlines - Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 12 July 2020Source: Journal of EthnopharmacologyAuthor(s): Mengyue Guo, Wenjun Jiang, Jingsheng Yu, Xiaohui Pang
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Source: Infection and Drug Resistance - Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
More News: Academia | Acute Leukemia | Acute Myeloid Leukemia | Adenocarcinoma | Biotechnology | Bone Cancers | Brain | Brain Cancers | Brain Tumor | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer in Adolescents | Carcinoma | China Health | Colon Cancer | Colorectal Cancer | Databases & Libraries | Epithelial Cancer | Genetics | Germany Health | Glioma | Grants | Hepatocellular Carcinoma | Hormone Refractory Prostate Cancer | Hormones | Japan Health | Laboratory Medicine | Legislation | Leukemia | Liver | Liver Cancer | Lung Cancer | Medical Ethics | Medulloblastoma | Men | Molecular Biology | Netherlands Health | Neurology | Neuroscience | Neurosurgery | Osteosarcoma | Pancreas | Pancreatic Cancer | Pediatrics | Prostate Cancer | Reproduction Medicine | Sodium | Statistics | Students | Study | Universities & Medical Training | Urology & Nephrology | Wilm's Tumor | Zinc